Detailed information for compound 27591
Basic information
Technical information
- TDR Targets ID: 27591
- Name: 4-amino-N-(2,6-dimethylphenyl)benzamide
- MW: 240.3 | Formula: C15H16N2O
-
H donors: 2
H acceptors: 1
LogP: 2.81
Rotable bonds: 3
Rule of 5 violations (Lipinski): 1 - SMILES: O=C(c1ccc(cc1)N)Nc1c(C)cccc1C
- InChi: 1S/C15H16N2O/c1-10-4-3-5-11(2)14(10)17-15(18)12-6-8-13(16)9-7-12/h3-9H,16H2,1-2H3,(H,17,18)
- InChiKey: HZIWGOAXOBPQGY-UHFFFAOYSA-N
Network
Hover on a compound node to display the structore
Synonyms
- 4-azanyl-N-(2,6-dimethylphenyl)benzamide
- ameltolide
- 787-93-9
- LY-201116
- AIDS089090
- Ameltolide (USAN/INN)
- D02892
- ZINC00004579
- ALD-N033185
- 2',6'-BENZOXYLIDIDE, 4-AMINO-
- 4-Amino-2',6'-benzoxylidide
- ADD 75073
- Ameltolida [INN-Spanish]
- Ameltolide [USAN:BAN:INN]
- Ameltolidum [INN-Latin]
- BRN 2734562
- Benzamide, 4-amino-N-(2,6-dimethylphenyl)-
- AIDS-089090
- C11485
- LY201116
- ADD-75073
Targets
Known targets for this compound
No curated genes were found associated with this compound
Predicted pathogen targets for this compound
By orthology
No druggable targets predicted by orthology data
By sequence similarity to non orthologous known druggable targets
No druggable targets predicted by sequence similarity
Obtained from network model
Ranking Plot
Putative Targets List
| Species | Potential target | Raw | Global | Species |
|---|---|---|---|---|
| Entamoeba histolytica | adenosine deaminase, putative | 0.028 | 1 | 0.5 |
| Mycobacterium ulcerans | adenosine deaminase | 0.028 | 1 | 0.5 |
| Toxoplasma gondii | Adenosine/AMP deaminase domain-containing protein | 0.028 | 1 | 0.5 |
| Mycobacterium leprae | Probable adenosine deaminase Add (ADENOSINE AMINOHYDROLASE) | 0.028 | 1 | 0.5 |
| Schistosoma mansoni | adenosine deaminase-related | 0.028 | 1 | 0.5 |
| Trichomonas vaginalis | adenosine deaminase, putative | 0.028 | 1 | 0.5 |
| Entamoeba histolytica | adenosine deaminase, putative | 0.028 | 1 | 0.5 |
| Plasmodium vivax | adenosine deaminase, putative | 0.028 | 1 | 0.5 |
| Leishmania major | adenine aminohydrolase | 0.028 | 1 | 0.5 |
| Toxoplasma gondii | Adenosine/AMP deaminase domain-containing protein | 0.028 | 1 | 0.5 |
| Treponema pallidum | adenosine deaminase | 0.028 | 1 | 0.5 |
| Echinococcus granulosus | adenosine deaminase | 0.028 | 1 | 0.5 |
| Onchocerca volvulus | Adenosine deaminase homolog | 0.028 | 1 | 0.5 |
| Trichomonas vaginalis | adenosine deaminase, putative | 0.028 | 1 | 0.5 |
| Mycobacterium tuberculosis | Probable adenosine deaminase Add (adenosine aminohydrolase) | 0.028 | 1 | 0.5 |
| Schistosoma mansoni | adenosine deaminase | 0.028 | 1 | 0.5 |
| Echinococcus multilocularis | adenosine deaminase | 0.028 | 1 | 0.5 |
| Plasmodium falciparum | adenosine deaminase | 0.028 | 1 | 0.5 |
| Loa Loa (eye worm) | hypothetical protein | 0.028 | 1 | 1 |
Activities
| Activity type | Activity value | Assay description | Source | Reference |
|---|---|---|---|---|
| Activity (functional) | Anticonvulsant activity determined at 4 hours after the administration of compound using MES test.(++= signify activity at 100 mg/kg) | ChEMBL. | 9719582 | |
| Activity (functional) | Anticonvulsant activity determined at 30 minutes after the administration of compound using MES test. (+++ = activity at 30 mg/kg) | ChEMBL. | 9719582 | |
| Activity (functional) | Anticonvulsant activity determined at 30 minutes after the administration of compound using sc Ptz test.(- denotes activity at 300 mg/kg) | ChEMBL. | 9719582 | |
| Activity (functional) | Anticonvulsant activity determined at 4 hours after the administration of compound using sc Ptz test.(- denotes activity at 300 mg/kg) | ChEMBL. | 9719582 | |
| Activity (functional) | + 0 | Anticonvulsant activity determined at 30 minutes after the administration of compound using MES test. (+++ = activity at 30 mg/kg) | ChEMBL. | 9719582 |
| Activity (functional) | 0 | Anticonvulsant activity determined at 4 hours after the administration of compound using MES test.(++= signify activity at 100 mg/kg) | ChEMBL. | 9719582 |
| Activity (functional) | NT 0 | Anticonvulsant activity determined at 30 minutes after the administration of compound using sc Ptz test.(- denotes activity at 300 mg/kg) | ChEMBL. | 9719582 |
| Activity (functional) | NT 0 | Anticonvulsant activity determined at 4 hours after the administration of compound using sc Ptz test.(- denotes activity at 300 mg/kg) | ChEMBL. | 9719582 |
| Activity (ADMET) | 0 | Neurotoxicity determined at 30 minutes after the administration of compound by rotorod test.(- denotes activity at 300 mg/kg) | ChEMBL. | 9719582 |
| Activity (ADMET) | 0 | Neurotoxicity determined at 4 hours after the administration of compound by rotorod test(- denotes activity at 300 mg/kg) | ChEMBL. | 9719582 |
| Activity (functional) | ++ 0 | Anticonvulsant activity was determined in rats at a dose of 30 mg/kg after 15 minutes by MES test. (++++ denotes activity in 75-100% of administered animals) | ChEMBL. | 9719582 |
| Activity (functional) | ++ 0 | Anticonvulsant activity was determined in rats at a dose of 30 mg/kg after 30 minutes by MES test. (++++ denotes activity in 75-100% of administered animals) | ChEMBL. | 9719582 |
| Activity (functional) | ++ 0 | Anticonvulsant activity was determined in rats at a dose of 30 mg/kg after 1 hour by MES test. (++++ denotes activity in 75-100% of administered animals) | ChEMBL. | 9719582 |
| Activity (functional) | ++ 0 | Anticonvulsant activity was determined in rats at a dose of 30 mg/kg after 2 hour by MES test. (++++ denotes activity in 75-100% of administered animals) | ChEMBL. | 9719582 |
| Activity (functional) | ++ 0 | Anticonvulsant activity was determined in rats at a dose of 30 mg/kg after 4 hour by MES test. (++++ denotes activity in 75-100% of administered animals) | ChEMBL. | 9719582 |
| Activity (ADMET) | 0 | Toxicity was determined in rats at a dose of 30 mg/kg after 4 hour . (- denotes no activity in administered animals). | ChEMBL. | 9719582 |
| Activity (functional) | 0 | Anticonvulsant activity of 30 mg/kg of the compound after 30 min. of intraperitoneal administration in mice against maximum electroschock seizures (MES); compound shows activity | ChEMBL. | 4032429 |
| Activity (functional) | 0 | Anticonvulsant activity of 30 mg/kg of the compound after 4 hr of intraperitoneal administration in mice against maximum electroschock seizures (MES); compound shows activity | ChEMBL. | 4032429 |
| Activity (functional) | 0 | Anticonvulsant activity of 300 mg/kg of compound against subcutaneous induced metrazole convulsions at interval of 30 min administered intraperitoneally in mice; no activity | ChEMBL. | 4032429 |
| Activity (functional) | 0 | Anticonvulsant activity of 300 mg/kg of compound against subcutaneous induced metrazole convulsions at interval of 4 hr administered intraperitoneally in mice; no activity | ChEMBL. | 4032429 |
| Concentration (functional) | = 299 ng ml-1 | Plasma concentration was determined after 360 min of oral administration of the compound in mice | ChEMBL. | 3656350 |
| Concentration (functional) | = 299 ng ml-1 | Plasma concentration was determined after 360 min of oral administration of the compound in mice | ChEMBL. | 3656350 |
| Concentration (functional) | = 394 ng ml-1 | Plasma concentration was determined after 240 min of oral administration of the compound in mice | ChEMBL. | 3656350 |
| Concentration (functional) | = 394 ng ml-1 | Plasma concentration was determined after 240 min of oral administration of the compound in mice | ChEMBL. | 3656350 |
| Concentration (functional) | = 656 ng ml-1 | Plasma concentration was determined after 120 min of oral administration of the compound in mice | ChEMBL. | 3656350 |
| Concentration (functional) | = 656 ng ml-1 | Plasma concentration was determined after 120 min of oral administration of the compound in mice | ChEMBL. | 3656350 |
| Concentration (functional) | = 893 ng ml-1 | Plasma concentration was determined after 60 min of oral administration of the compound in mice | ChEMBL. | 3656350 |
| Concentration (functional) | = 893 ng ml-1 | Plasma concentration was determined after 60 min of oral administration of the compound in mice | ChEMBL. | 3656350 |
| Concentration (functional) | = 1088 ng ml-1 | Plasma concentration was determined after 30 min of oral administration of the compound in mice | ChEMBL. | 3656350 |
| Concentration (functional) | = 1088 ng ml-1 | Plasma concentration was determined after 30 min of oral administration of the compound in mice | ChEMBL. | 3656350 |
| ED50 (functional) | = 1.4 mg kg-1 | Anticonvulsant effect of the compound was determined by maximal electroshock assay in mice after peroral administration. | ChEMBL. | 2016702 |
| ED50 (functional) | = 1.4 mg kg-1 | Anticonvulsant effect of the compound was determined by maximal electroshock assay in mice after peroral administration. | ChEMBL. | 2016702 |
| ED50 (functional) | = 1.7 mg kg-1 | Antagonistic activity against MES (Maximal Elecroshock)-induced seizures after oral administration to mice | ChEMBL. | 3656350 |
| ED50 (functional) | = 1.7 mg kg-1 | Antagonistic activity against MES (Maximal Elecroshock)-induced seizures after oral administration to mice | ChEMBL. | 3656350 |
| ED50 (functional) | = 2.6 mg kg-1 | Effective dose evaluated against maximal electric seizures (MES) or convulsions in mice ; activity value ranges from 2.18-3.07 | ChEMBL. | 4032429 |
| ED50 (functional) | = 2.6 mg kg-1 | Compound for anticonvulsant activity against maximal electroshock (MES)-induced seizures in mice after administration | ChEMBL. | 3735320 |
| ED50 (functional) | = 2.6 mg kg-1 | Effective dose evaluated against maximal electric seizures (MES) or convulsions in mice ; activity value ranges from 2.18-3.07 | ChEMBL. | 4032429 |
| ED50 (functional) | = 2.6 mg kg-1 | Compound for anticonvulsant activity against maximal electroshock (MES)-induced seizures in mice after administration | ChEMBL. | 3735320 |
| ED50 (functional) | = 13 mg kg-1 | In vivo anticonvulsant activity to prevent seizures from maximum electroshock (MES) in rat hippocampal slices | ChEMBL. | 11170622 |
| ED50 (functional) | = 19.9 mg kg-1 | Anticonvulsant effect of the compound was determined by maximal electroshock assay in mice after intravenous administration. | ChEMBL. | 2016702 |
| ED50 (functional) | = 19.9 mg kg-1 | Anticonvulsant effect of the compound was determined by maximal electroshock assay in mice after intravenous administration. | ChEMBL. | 2016702 |
| ED50 (functional) | = 23 mg kg-1 | Anticonvulsant effect of the compound was determined by horizontal screen assay in mice after peroral administration. | ChEMBL. | 2016702 |
| ED50 (functional) | = 23 mg kg-1 | Ataxia or neurological deficit was measured as horizontal screen test(HS) in mice | ChEMBL. | 3656350 |
| ED50 (functional) | = 23 mg kg-1 | Anticonvulsant effect of the compound was determined by horizontal screen assay in mice after peroral administration. | ChEMBL. | 2016702 |
| ED50 (functional) | = 23 mg kg-1 | Ataxia or neurological deficit was measured as horizontal screen test(HS) in mice | ChEMBL. | 3656350 |
| ED50 (functional) | = 135 uM kg-1 | Anticonvulsant ED50 activity by MES test in rats dosed orally | ChEMBL. | 9719582 |
| IC50 (binding) | = 0.97 uM | Apparent IC50 value by [3H]-batrachotoxinin-A-20-alpha-benzoate-binding test performed in rat brain synaptosomes | ChEMBL. | 9719582 |
| PI (ADMET) | = 3.17 | Protective index measured as the ratio between TD50 and ED50 | ChEMBL. | 3735320 |
| PI (ADMET) | = 5.77 | Protective index of the compound as the ratio of TD50 value against MES to that of ED50 value against MES. | ChEMBL. | 4032429 |
| PI (functional) | = 13 | Protective index (HS ED50/MES ED50) after oral administration in mice | ChEMBL. | 3656350 |
| Protective index (functional) | = 13 | Protective index measured as the ratio of HS ED50/MES ED50 values. | ChEMBL. | 2016702 |
| Sleeping time (functional) | = 59.6 min | Effect of the compound on Hexobarbitol-Induced sleeping time in mice at a dose of 0 mg/kg peroral administration | ChEMBL. | 3656350 |
| Sleeping time (functional) | = 59.6 min | Effect of the compound on Hexobarbitol-Induced sleeping time in mice at a dose of 0 mg/kg peroral administration | ChEMBL. | 3656350 |
| Sleeping time (functional) | = 67.9 min | Effect of the compound on Hexobarbitol-Induced sleeping time in mice at a dose of 1.6 mg/kg peroral administration | ChEMBL. | 3656350 |
| Sleeping time (functional) | = 67.9 min | Effect of the compound on Hexobarbitol-Induced sleeping time in mice at a dose of 1.6 mg/kg peroral administration | ChEMBL. | 3656350 |
| Sleeping time (functional) | = 69.3 min | Effect of the compound on Hexobarbitol-Induced sleeping time in mice at a dose of 3.2 mg/kg peroral administration | ChEMBL. | 3656350 |
| Sleeping time (functional) | = 69.3 min | Effect of the compound on Hexobarbitol-Induced sleeping time in mice at a dose of 3.2 mg/kg peroral administration | ChEMBL. | 3656350 |
| Sleeping time (functional) | = 75 min | Effect of the compound on Hexobarbitol-Induced sleeping time in mice at a dose of 6.4 mg/kg peroral administration | ChEMBL. | 3656350 |
| Sleeping time (functional) | = 75 min | Effect of the compound on Hexobarbitol-Induced sleeping time in mice at a dose of 6.4 mg/kg peroral administration | ChEMBL. | 3656350 |
| Sleeping time (functional) | = 76.4 min | Effect of the compound on Hexobarbitol-Induced sleeping time in mice at a dose of 12.8 mg/kg peroral administration | ChEMBL. | 3656350 |
| Sleeping time (functional) | = 76.4 min | Effect of the compound on Hexobarbitol-Induced sleeping time in mice at a dose of 12.8 mg/kg peroral administration | ChEMBL. | 3656350 |
| TD50 (ADMET) | = 15 mg kg-1 | Compound for toxicity by rotorod assay method in mice after administration | ChEMBL. | 3735320 |
| TD50 (ADMET) | = 15 mg kg-1 | Compound for toxicity by rotorod assay method in mice after administration | ChEMBL. | 3735320 |
| TD50 (ADMET) | = 15.01 mg kg-1 | Toxic dose was determined by the rotorod test in mice; activity value ranges from 13.27-16.88 | ChEMBL. | 4032429 |
| TD50 (ADMET) | = 15.01 mg kg-1 | Toxic dose was determined by the rotorod test in mice; activity value ranges from 13.27-16.88 | ChEMBL. | 4032429 |
| Toxicity (ADMET) | 0 | Toxicity tested by rotorod test for neurologic deficit at interval of 30 min when 30 mg/kg was administered intraperitoneally; shows activity | ChEMBL. | 4032429 |
| Toxicity (ADMET) | 0 | Toxicity tested by rotorod test for neurologic deficit at interval of 4 hr when 100 mg/kg was administered intraperitoneally; shows activity | ChEMBL. | 4032429 |
| TPE (functional) | = 0.5 hr | Time to peak anticonvulsant effect of the compound was measured after oral dosing in mice. | ChEMBL. | 2016702 |
| TPE (functional) | = 0.5 hr | Time taken for peak anticonvulsant effect(TPE) was measured by oral administration to mice | ChEMBL. | 3656350 |
| TPE (functional) | = 0.5 hr | Time to peak anticonvulsant effect of the compound was measured after oral dosing in mice. | ChEMBL. | 2016702 |
| TPE (functional) | = 0.5 hr | Time taken for peak anticonvulsant effect(TPE) was measured by oral administration to mice | ChEMBL. | 3656350 |
Phenotypes
Whole-cell/tissue/organism interactions
We have no records of whole-cell/tissue assays done with this compound
What does this mean?
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
Annotated phenotypes:
We have no manually annotated phenotypes for this drug.
What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by
drugs, or by genetic manipulation of cells (e.g. gene knockouts or
knockdowns) is manually curated from the literature. These
descriptions help to describe the potential of the target for drug
development. If no information is available for this gene or if the
information is incomplete, this may mean that i) the papers
containing this information either appeared after the curation
effort for this organism was carried out or they were inadvertently
missed by curators; or that ii) the curation effort for this
organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.
External resources for this compound
- Search by CAS
- ChEMBL: CHEMBL22916
- PubChem: 13086
Bibliographic References
6 literature references were collected for this gene.
If you have references for this compound, please enter them in a user comment (below) or Contact us.